Genmab — Juli 2018
-
Fra nummer fire hedder det: "Overall the therapeutic studies demonstrate that combination CD38 and PD-L1 blockade substantially reduces primary tumor burden and
metastases, that CD38 can be used in combination or in a sequential manner upon the
acquisition of resistance, and that targeting CD38 or the downstream adenosine
signaling is highly effective. -
To model how CD38-blocking strategies might be translated into the clinic for patients
with disease refractory to anti-PD-1/PD-L1, we tested sequential treatment after the
development of resistance to anti-PD-L1 by treating animals with anti-CD38 antibody
alone. -
We observed a substantial inhibition of tumor growth with an associated
enhancement of the effector CD8+
and CD4+
T cell responses and blunting of the
suppressor CD4+
T regulatory and MDSC populations, highlighting that CD38 is an
independent factor in treatment-induced resistance -
Kildeangivelse: Downloaded from cancerdiscovery.aacrjournals.org on July 21, 2018.
2018 American Association for Cancer Research -
Jeg er med på safetyproblemet, men konklusionen er stadigvæk, at "The mechanism of immune resistance to anti-PDL1/PD-1
therapy caused by CD38 provides an evident rationale for recruitment of
cancer patients for clinical trials of anti-CD38 in combination with anti-PD-L1/PD-1 to
prevent therapy resistance and further enhance anti-tumor efficacy."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind